SPP1 and rheumatoid arthritis: Nevertheless, when ASK8007 was administrated in RA patients with active, moderate, and severe disease, it did not affect the inflammation or joint destruction; however, it increased the OPN shedding from the endothelium by binding to OPN and forming OPN–ASK8007 complexes, resulting in systemic and partly bioactive OPN accumulation.